Market Access · Pricing · Policy

Access strategy for
a repriced world.

The rules governing how drugs get assessed, priced, and accessed are being rewritten simultaneously. We help biotech and pharma leadership navigate what's coming – before it becomes a crisis.

Our services ▶  Watch our story Point of View
The challenge

Where access strategy breaks down – and what to do before it does.

JCA has changed when EU access strategy must begin. MFN is linking US prices to European HTA outcomes. Cost-effectiveness thresholds are being reset by trade negotiations, not health economics. Most teams are treating these as separate challenges. They're not – and that's where strategy breaks down. Our work starts at that intersection.

“Scientific breakthroughs don’t change communities.
Access to them does.
We help the businesses creating tomorrow’s medicines close that gap.”

Latif Strategic Advisory – Mission

LSA Film

Access strategy,
in our own words.

A short film about the work Latif Strategic Advisory does, why it matters, and the people it serves. Produced in London – coming Autumn 2026.

Coming Autumn 2026

Latif Strategic Advisory

Services

Focused engagements.
Decision-ready outputs.

Short-burn, high-impact work designed for the moments when the standard playbook doesn't apply and the stakes are high. Scope, duration, and fees are tailored to the complexity of each situation – initial engagements typically start from 1–2 weeks.

01

Phase 2 Exit Readiness: EU Access Positioning

Rapid assessment of EU access viability, pricing corridor, HTA risks, and launch sequencing – designed for asset partnering and out-licensing readiness. Payer credibility drives asset valuation.

Outputs

Pricing corridor · Access feasibility · HTA risk map · Key trade-offs and strategic options

Scoped to complexityFrom 1–2 weeks
02

Evidence → HTA Translation Sprint

Translate complex, early, or imperfect evidence into a credible payer narrative. Identify where your evidence package holds under EU HTA scrutiny – and where it doesn't. Build a mitigation strategy around what's missing.

Outputs

Value story · HTA risk assessment · Evidence gap analysis · Mitigation strategy

Scoped to complexityFrom 1–2 weeks
03

Policy Risk & Pricing Scenario Map

Scenario modelling under EU HTA, IRP, and MFN pressure. Understand the pricing implications of the current policy environment and build a sequencing strategy that holds across scenarios.

Outputs

Scenario map · Strategic pricing options · Launch sequencing framework · Risk-adjusted recommendations

Scoped to complexityFrom 1–2 weeks
Emerging Verticals

Two high-growth practice areas in active development – reflecting where market demand is moving and where LSA has established a differentiated position.

Emerging vertical

Market Access Due Diligence & Advisory for Healthcare PE

Specialist due diligence and strategic advisory for private equity firms evaluating life sciences investments. We assess access strategy credibility, reimbursement risk, and pricing corridor feasibility at the asset level – helping PE teams price access risk accurately, challenge management assumptions, and support portfolio companies through regulatory and HTA transition points.

Active conversations with growth equity and healthcare-focused PE funds across the UK and US. An underserved capability gap as PE activity in pharma services and late-stage biotech intensifies.

Scope

Investment-stage MA diligence · Portfolio company access advisory · Reimbursement risk assessment · HTA readiness

Emerging vertical

Access-Sustainability: Integrated Advisory

In collaboration with Context Group

CSRD, ESG, and affordability obligations are no longer peripheral to access strategy – they are entering the commercial conversation directly. We help pharma and biotech leadership integrate sustainability positioning into payer engagement, stakeholder communications, and access planning, addressing the growing requirement for CSRD compliance to inform rather than conflict with commercial strategy.

Scope

Access & sustainability integration · CSRD advisory · ESG stakeholder strategy · Payer communications

How we work

Well-designed access strategies unravel when evidence, policy, and commercial expectations diverge – and no one is holding the thread clearly enough to act.

—

Focused by design. Initial engagements typically start from 1–2 weeks – scope and duration are always tailored to the complexity of your situation.

—

Decision-ready outputs: specific trade-offs, risk-adjusted scenarios, a direction the team can act on.

—

Grounded in technical depth – HEOR, HTA, pricing – and front-line commercial experience from in-house and advisory roles across European oncology and rare disease.

—

The thinking that makes complex access challenges tractable – upstream of the large consultancy model, not subordinate to it.

About

Independent. Senior.
In the room.

Faisal Latif

"Most access strategies don't fail on design – they fail when evidence, policy and commercial expectations diverge. I help teams find the path through."

Latif Strategic Advisory is an independent consultancy at the intersection of market access, pricing, evidence strategy, and policy. Founded by Faisal Latif, who combines in-house operator experience with senior advisory practice across European and global life sciences.

At Bristol Myers Squibb, Faisal led HEOR for the flagship thoracic oncology portfolio at the UK affiliate, delivering NICE reimbursement for the breakthrough indication in first-line lung cancer, before moving into global access and pricing, ultimately heading the EU Cluster Value, Access & Pricing organisation. At IQVIA, as Senior Principal in Value & Access within the EMEA Life Sciences Strategy practice, he directed advisory mandates helping global and ex-US leadership navigate rapidly evolving regulatory and policy dynamics – EU JCA, IRA, and MFN – to build launch and pricing strategy across Europe and Asia.

LSA works at the point where access strategy becomes a live commercial challenge – when evidence is still evolving, policy is shifting, and the distance between what's planned and what's achievable is starting to show.

Founder Latif Strategic Advisory
Senior Principal · Value & Access, EMEA Life Sciences Strategy IQVIA
Head, EU Cluster · Value, Access & Pricing Bristol Myers Squibb
HEOR Lead, Thoracic Oncology · UK Affiliate Bristol Myers Squibb
MSc, Health Economics & International Health Policy The London School of Economics and Political Science

Focus areas

EU HTA (JCA) · Pricing strategy · MFN/IRP · Early access planning · Oncology

Strategic Partners

Built to deliver
at every layer.

Latif Strategic Advisory works with a select group of specialist partners – enabling deployment across AI-enabled access platforms, sustainability advisory, health equity intelligence, and sector-specific expertise that would otherwise sit outside the reach of a boutique firm.

Formal announcement coming
Context Group
Access · Sustainability · Communications

A specialist consultancy at the intersection of market access and corporate sustainability – bringing environmental, social, and governance intelligence into the commercial access conversation. Together, LSA and Context Group address the growing requirement for pharma leadership to integrate CSRD, affordability, and ESG positioning into access strategy.

Joint focus

Access & sustainability strategy · CSRD advisory · Stakeholder communications

Formal announcement coming
Access Infinity
AI-Enabled Market Access Platform

A leading AI-native platform purpose-built for market access teams – combining evidence synthesis, HTA intelligence, payer negotiation simulation, and enterprise knowledge management. The partnership enables LSA to offer AI-accelerated delivery across dossier production, payer preparation, and access intelligence workflows.

Joint focus

AI-enabled dossier acceleration · HTA negotiation simulation · Access knowledge infrastructure

Partnership in development
Access to Medicine Foundation
Health Equity · Global Access · LMIC Strategy

An independent, internationally recognised foundation that measures and drives pharmaceutical companies' efforts to improve access to medicine in lower-income countries. Access to medicine in lower-income settings is a personal motivation — not a footnote. In partnership with ATMF, LSA is developing an emerging practice that connects the tools and intelligence built in high-income markets to where the gap between scientific progress and patient reach is widest. It is the longer ambition this firm was built toward.

Joint focus

LMIC access strategy · Health equity frameworks · Access-to-medicine intelligence · HIC–LMIC translation

Expert Advisory Panel

Senior expertise.
Independent perspective.

Amadou Diarra

Amadou Diarra, Ph.D.

Former SVP, Global Policy, Advocacy & Government Affairs · Bristol Myers Squibb

Three decades at BMS, spanning general manager roles across four continents before leading global policy, patient advocacy, and government affairs at SVP level. Former Chair, BioNJ; former Chair, IFPMA Council. Deep expertise in global access, policy architecture, and institutional engagement across the US, Europe, and emerging markets.

Princeton, NJ

Emmanuel Chantelot

Emmanuel Chantelot

Managing Director, Healthcare & Corporate Advisory · Former VP, International Policy & Government Affairs

Thirty years in international public affairs, with two decades in senior healthcare leadership across BMS, Pfizer, Celgene, Shire, and EFPIA. Held VP-level policy and government affairs roles at two major global biopharma companies before moving into senior advisory practice. Specialist in EU policy navigation, HTA reform, and regulatory–commercial interface.

Brussels, Belgium

Further members being confirmed

Formal panel announcement coming

Point of View

Point of View.

MFN and EU HTA reform are repricing European pharma simultaneously – and the exposure compounds. These pieces examine what the data shows and what it means for access and pricing strategy.

New Leadership Life Sciences Purpose

The highs are real. So are the difficult days.

Building a boutique advisory firm is exhilarating. It is also deeply uncomfortable. An honest account of what building LSA actually looks like – the momentum, the difficult days, and the longer mission underneath it all.

26 August 2026 Faisal Latif 5 min read Full article →
Leadership Operating Discipline Life Sciences

What a cardiac patient learned about building an advisory firm: notes on operating discipline

In twenty-two weeks, two projects ran simultaneously: reversing a decade of metabolic decline and building a specialist advisory firm. The same operating discipline drove both. The transfer wasn't accidental.

30 July 2026 · Full article · 7 min read
HTA CSRD Environmental

By the time a drug reaches NICE, the environmental damage is already done.

The OHE is asking whether HTA should factor in environmental impact. But HTA isn't the lever. By the time a submission lands at NICE, the carbon is locked in. CSRD operates upstream – and it's already in force.

7 July 2026 · Full article · 4 min read
MFN JCA Evidence

The Compounding Is Real. Here's What the Data Shows.

A peer-reviewed analysis puts empirical numbers on the MFN × JCA pressure for the first time. Launch rates in JCA states fell 37.8%. The orphan differential hit 22%. The findings are sharper than anticipated.

23 June 2026 · Full article · 4 min read
MFN Europe Pricing

Go Ahead – De-Prioritise Europe. You Can't De-Prioritise the Exposure.

MFN doesn't just benchmark US prices against European ones. It creates a feedback loop: a weaker European deal weakens every future US negotiation. The exposure doesn't wait for you to decide whether Europe is strategic.

11 June 2026 · Co-authored with JMUN Advisors · 5 min read
Market Access Strategy

The EU Access Playbook Is Breaking.

Most access strategies aren't failing on design. They're failing because three forces have made the old model structurally unworkable – and most organisations haven't caught up yet.

29 May 2026 · Full article
Biotech Innovation Pricing

China's biotech surge is being framed as an innovation story. It's also a pricing story.

The dynamics reshaping global biotech competition have implications for European launch sequencing and reference pricing that the industry hasn't fully priced in.

20 May 2026 · Full article
CSRD Policy Access

Pharma is treating CSRD as a sustainability reporting problem. It's an access strategy problem.

The Corporate Sustainability Reporting Directive creates disclosure obligations that intersect directly with pricing, access, and affordability commitments – and most commercial teams aren't in the room.

18 May 2026 · Full article

 LinkedIn
MFN Europe Pricing

Albert Bourla wrote directly to the German Chancellor. The system has changed.

When a major pharma CEO bypasses normal channels and addresses a head of government directly on drug pricing, it signals that the established negotiation architecture is under genuine strain.

14 May 2026

 LinkedIn
HTA Policy

NICE thresholds are no longer purely a health economics tool. They are instruments of trade policy.

The first threshold change since NICE was founded in 1999 – announced alongside a trade deal. The technical clothing remains. The emperor underneath has changed.

12 May 2026

 LinkedIn
MFN Market Access

Senior leadership is hedging on MFN. Market access teams can't.

With GLOBE taking effect October 1, the decisions being made in the vacuum of leadership silence are still decisions. They're just being made by default instead of by design.

7 May 2026
Selected Work

Engagements that
shaped decisions.

A selection of advisory engagements. Client details are anonymised.

Oncology Companion Diagnostics Market Access

Companion Diagnostic Access Strategy

A major global oncology alliance was preparing to launch a novel ADC asset in platinum-resistant ovarian cancer requiring a companion diagnostic to identify eligible patients. Across 17 European and select international markets, CDx reimbursement pathways were fragmented, inconsistent, and in many cases untested for novel IHC-based diagnostics.

A structured three-phase engagement mapped CDx funding pathways and key stakeholders across all markets, segmented by gap severity and mitigation feasibility, and produced a strategic playbook covering 7+ actionable options – each assessed by timing, effort, and risk. The alliance entered launch sequencing with a defensible, evidence-based playbook.

17
Markets covered
8–9 wks
Delivery sprint
>€100K
Engagement value
Won
Competitive mandate
View case study →
Immunology EU HTA Pricing Strategy

EU HTA Advisory & Early Access Strategy

A US-headquartered specialty biopharma was preparing simultaneous HTA submissions in three major EU markets for a novel oral treatment in a moderate-to-severe immunological condition – the first in its mechanism class to reach late-stage development. With NICE, G-BA, and HAS submissions running in parallel, the team needed rapid, independent advisory support.

A focused two-week sprint reviewed the evidence package against current HTA methodology in each market, identified where the value story was vulnerable, and produced a concise HTA risk map. The engagement led to a follow-on mandate covering scenario modelling under EU HTA and IRP, and a pricing corridor framework adopted as the basis for the global launch plan.

3
HTA markets
2 wks
Initial sprint
6 months
Pre-assessment delivery
Won
Follow-on mandate
View case study →
Contact

Start a conversation.

If your access strategy is facing a moment of complexity – early data, shifting policy, a partnership or launch decision – get in touch.

Email faisal@latifstrategic.co.uk
LinkedIn linkedin.com/in/faisallatif
Web latifstrategic.com